Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer
· Curasight’s radiopharmaceutical approach leverages the uPAR theranostic platform with the aim of providing improved diagnosis (uTRACE) and more gentle treatment (uTREAT) of certain types of cancers · Data from the Phase II uTRACE trial is now published in full in the peer-reviewed journal EJNMMI Research Copenhagen, Denmark, 7 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the investigator-initiated phase II study using uPAR-PET in brain cancer has been publishedThe investigator-initiated clinical trial testing [68]Ga-NOTA-AE105